Xin Tracy Liu,Yu Huang,Da Liu,Yingxin Celia Jiang,Min Zhao,Long Hoa Chung,Xingxing Daisy Han,Yinan Zhao,Jinbiao Chen,Paul Coleman,Ka Ka Ting,Collin Tran,Yingying Su,Claude Vincent Dennis,Atul Bhatnagar,Ken Liu,Anthony Simon Don,Mathew Alexander Vadas,Mark Douglas Gorrell,Shubiao Zhang,Michael Murray,Mary Meltem Kavurma,Geoffrey William McCaughan,Jennifer Ruth Gamble,Yanfei Qi

Abstract:Hepatocellular carcinoma (HCC) remains a leading life-threatening health challenge worldwide, with pressing needs for novel therapeutic strategies. Sphingosine kinase 1 (SphK1), a well-established pro-cancer enzyme, is aberrantly overexpressed in a multitude of malignancies, including HCC. Our previous research has shown that genetic ablation of Sphk1 mitigates HCC progression in mice. Therefore, the development of PF-543, a highly selective SphK1 inhibitor, opens a new avenue for HCC treatment. However, the anti-cancer efficacy of PF-543 has not yet been investigated in primary cancer models in vivo, thereby limiting its further translation.

Targeting the SphK1/S1P/PFKFB3 axis suppresses hepatocellular carcinoma progression by disrupting glycolytic energy supply that drives tumor angiogenesis